Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Year Data in uHCC
The HIMALAYA study's 5-year data revealed that the combination of tremelimumab and durvalumab improved overall survival in unresectable hepatocellular carcinoma patients, with a 5-year survival rate of 19.6% compared to 9.4% with sorafenib. This combination, known as STRIDE, showed sustained OS benefits and deeper tumor responses, setting new standards in uHCC treatment.
Related Clinical Trials
Reference News
Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Year Data in uHCC
The HIMALAYA study's 5-year data revealed that the combination of tremelimumab and durvalumab improved overall survival in unresectable hepatocellular carcinoma patients, with a 5-year survival rate of 19.6% compared to 9.4% with sorafenib. This combination, known as STRIDE, showed sustained OS benefits and deeper tumor responses, setting new standards in uHCC treatment.